233 related articles for article (PubMed ID: 21871056)
1. sRAGE in diabetic and non-diabetic critically ill patients: effects of intensive insulin therapy.
Arabi YM; Dehbi M; Rishu AH; Baturcam E; Kahoul SH; Brits RJ; Naidu B; Bouchama A
Crit Care; 2011 Aug; 15(4):R203. PubMed ID: 21871056
[TBL] [Abstract][Full Text] [Related]
2. Soluble RAGE and the RAGE ligands HMGB1 and S100A12 in critical illness: impact of glycemic control with insulin and relation with clinical outcome.
Ingels C; Derese I; Wouters PJ; Van den Berghe G; Vanhorebeek I
Shock; 2015 Feb; 43(2):109-16. PubMed ID: 25394242
[TBL] [Abstract][Full Text] [Related]
3. Soluble receptor for advanced glycation end products in critically ill patients and its associations with other clinical markers and 28-day mortality.
Cheng Y; Zhong J; Xiang Y; Zeng F; Cai D; Zhao L
Clin Interv Aging; 2014; 9():1981-6. PubMed ID: 25429209
[TBL] [Abstract][Full Text] [Related]
4. Circulating soluble receptor for advanced glycation end products is inversely associated with glycemic control and S100A12 protein.
Basta G; Sironi AM; Lazzerini G; Del Turco S; Buzzigoli E; Casolaro A; Natali A; Ferrannini E; Gastaldelli A
J Clin Endocrinol Metab; 2006 Nov; 91(11):4628-34. PubMed ID: 16926247
[TBL] [Abstract][Full Text] [Related]
5. Positive association of serum levels of advanced glycation end products and high mobility group box-1 with asymmetric dimethylarginine in nondiabetic chronic kidney disease patients.
Nakamura T; Sato E; Fujiwara N; Kawagoe Y; Ueda Y; Suzuki T; Yamada S; Takeuchi M; Fukami K; Ueda S; Adachi H; Matsui T; Okuda S; Yamagishi S
Metabolism; 2009 Nov; 58(11):1624-8. PubMed ID: 19604520
[TBL] [Abstract][Full Text] [Related]
6. The Course of Skin and Serum Biomarkers of Advanced Glycation Endproducts and Its Association with Oxidative Stress, Inflammation, Disease Severity, and Mortality during ICU Admission in Critically Ill Patients: Results from a Prospective Pilot Study.
Meertens JH; Nienhuis HL; Lefrandt JD; Schalkwijk CG; Nyyssönen K; Ligtenberg JJ; Smit AJ; Zijlstra JG; Mulder DJ
PLoS One; 2016; 11(8):e0160893. PubMed ID: 27529340
[TBL] [Abstract][Full Text] [Related]
7. Effect of insulin on the soluble receptor for advanced glycation end products (RAGE).
Lam JK; Wang Y; Shiu SW; Wong Y; Betteridge DJ; Tan KC
Diabet Med; 2013 Jun; 30(6):702-9. PubMed ID: 23432638
[TBL] [Abstract][Full Text] [Related]
8. Association between serum levels of soluble receptor for advanced glycation end products and circulating advanced glycation end products in type 2 diabetes.
Tan KC; Shiu SW; Chow WS; Leng L; Bucala R; Betteridge DJ
Diabetologia; 2006 Nov; 49(11):2756-62. PubMed ID: 16969649
[TBL] [Abstract][Full Text] [Related]
9. Placental growth factor, pregnancy-associated plasma protein-A, soluble receptor for advanced glycation end products, extracellular newly identified receptor for receptor for advanced glycation end products binding protein and high mobility group box 1 levels in patients with acute kidney injury: a cross sectional study.
Zakiyanov O; Kriha V; Vachek J; Zima T; Tesar V; Kalousova M
BMC Nephrol; 2013 Nov; 14():245. PubMed ID: 24188108
[TBL] [Abstract][Full Text] [Related]
10. Soluble receptor for advanced glycation end products triggers a proinflammatory cytokine cascade via beta2 integrin Mac-1.
Pullerits R; Brisslert M; Jonsson IM; Tarkowski A
Arthritis Rheum; 2006 Dec; 54(12):3898-907. PubMed ID: 17133598
[TBL] [Abstract][Full Text] [Related]
11. Soluble RAGE in type 2 diabetes: association with oxidative stress.
Devangelio E; Santilli F; Formoso G; Ferroni P; Bucciarelli L; Michetti N; Clissa C; Ciabattoni G; Consoli A; Davì G
Free Radic Biol Med; 2007 Aug; 43(4):511-8. PubMed ID: 17640561
[TBL] [Abstract][Full Text] [Related]
12. Soluble receptor for advanced glycation end-products and progression of airway disease.
Iwamoto H; Gao J; Pulkkinen V; Toljamo T; Nieminen P; Mazur W
BMC Pulm Med; 2014 Apr; 14():68. PubMed ID: 24758342
[TBL] [Abstract][Full Text] [Related]
13. The soluble form of the receptor of advanced glycation endproducts increases after bariatric surgery in morbid obesity.
Brix JM; Höllerl F; Kopp HP; Schernthaner GH; Schernthaner G
Int J Obes (Lond); 2012 Nov; 36(11):1412-7. PubMed ID: 22828946
[TBL] [Abstract][Full Text] [Related]
14. Elevation of soluble form of receptor for advanced glycation end products (sRAGE) in diabetic subjects with coronary artery disease.
Nakamura K; Yamagishi S; Adachi H; Kurita-Nakamura Y; Matsui T; Yoshida T; Sato A; Imaizumi T
Diabetes Metab Res Rev; 2007 Jul; 23(5):368-71. PubMed ID: 17024691
[TBL] [Abstract][Full Text] [Related]
15. Serum levels of soluble form of receptor for advanced glycation end products (sRAGE) are positively associated with circulating AGEs and soluble form of VCAM-1 in patients with type 2 diabetes.
Nakamura K; Yamagishi S; Adachi H; Matsui T; Kurita-Nakamura Y; Takeuchi M; Inoue H; Imaizumi T
Microvasc Res; 2008 May; 76(1):52-6. PubMed ID: 18474381
[TBL] [Abstract][Full Text] [Related]
16. Thiazolidinedione increases serum soluble receptor for advanced glycation end-products in type 2 diabetes.
Tan KCB; Chow WS; Tso AWK; Xu A; Tse HF; Hoo RLC; Betteridge DJ; Lam KSL
Diabetologia; 2007 Sep; 50(9):1819-1825. PubMed ID: 17639302
[TBL] [Abstract][Full Text] [Related]
17. Glucose control and mortality in critically ill patients.
Finney SJ; Zekveld C; Elia A; Evans TW
JAMA; 2003 Oct; 290(15):2041-7. PubMed ID: 14559958
[TBL] [Abstract][Full Text] [Related]
18. Action of metformin therapy against advanced glycation, oxidative stress and inflammation in type 2 diabetes patients: 3 months follow-up study.
Adeshara KA; Bangar NS; Doshi PR; Diwan A; Tupe RS
Diabetes Metab Syndr; 2020; 14(5):1449-1458. PubMed ID: 32769032
[TBL] [Abstract][Full Text] [Related]
19. Serum levels of sRAGE, the soluble form of receptor for advanced glycation end products, are associated with inflammatory markers in patients with type 2 diabetes.
Nakamura K; Yamagishi S; Adachi H; Kurita-Nakamura Y; Matsui T; Yoshida T; Imaizumi T
Mol Med; 2007; 13(3-4):185-9. PubMed ID: 17592553
[TBL] [Abstract][Full Text] [Related]
20. Switching to multiple daily injection therapy with glulisine improves glycaemic control, vascular damage and treatment satisfaction in basal insulin glargine-injected diabetic patients.
Yanagisawa K; Ashihara J; Obara S; Wada N; Takeuchi M; Nishino Y; Maeda S; Ishibashi Y; Yamagishi S
Diabetes Metab Res Rev; 2014 Nov; 30(8):693-700. PubMed ID: 24639403
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
